Giles Campion
Nessuna posizione attualmente
Patrimonio netto: 79 200 $ in data 31/07/2023
Storia della carriera di Giles Campion
Precedenti posizioni note di Giles Campion
Società | Posizione | Inizio | Fine |
---|---|---|---|
SILENCE THERAPEUTICS PLC | Director/Board Member | 20/05/2020 | 01/04/2023 |
Chief Tech/Sci/R&D Officer | 01/06/2019 | 01/04/2023 | |
Albumedix Ltd.
Albumedix Ltd. BiotechnologyHealth Technology Part of Sartorius AG, Albumedix Ltd. is a British science-driven company and recognized leader of albumin-enabled solutions. The private company, based in Nottingham, UK, was founded in 1984 with a mission to empower excellence. Albumedix has supported its life-science partners in delivering safe doses of clinical and marketed therapeutics. The company's solutions include the world's only USP-NF compliant recombinant human albumin, client-centric development and compliance services, and drug-enhancing technologies. By challenging the status quo and striving for more, Albumedix enables the development and commercialization of advanced therapies and next-generation biopharmaceuticals. Albumedix is the world leader in recombinant human albumin and has developed a portfolio of products known as Recombumin®. Founded in 1973, the CEO of Albumedix is Jonas S. Moller. The company was acquired by Sartorius Stedim Biotech SA on September 30, 2022, for $500.47 million. | Chief Tech/Sci/R&D Officer | 01/01/2017 | 01/07/2018 |
BIOMARIN PHARMACEUTICAL INC. | Corporate Officer/Principal | 01/02/2015 | 01/03/2016 |
PROSENSA HOLDING NV | Chief Tech/Sci/R&D Officer | 01/05/2009 | 01/01/2016 |
PEPGEN INC. | Founder | 26/03/2018 | - |
Pepgen Ltd.
Pepgen Ltd. Packaged SoftwareTechnology Services Pepgen Ltd. engages in research and experimental development on biotechnology. The company was founded on January 25, 2018 and is headquartered in Oxford, the United Kingdom. | Founder | - | - |
Formazione di Giles Campion
University of Bristol | Doctorate Degree |
Statistiche
Distribuzione geografica
Regno Unito | 5 |
Stati Uniti | 3 |
Paesi Bassi | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 3 |
Founder | 2 |
Doctorate Degree | 1 |
Settori
Health Technology | 5 |
Commercial Services | 2 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
BIOMARIN PHARMACEUTICAL INC. | Health Technology |
SILENCE THERAPEUTICS PLC | Commercial Services |
PEPGEN INC. | Health Technology |
Aziende private | 3 |
---|---|
Prosensa Holding NV
Prosensa Holding NV BiotechnologyHealth Technology Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands. | Health Technology |
Pepgen Ltd.
Pepgen Ltd. Packaged SoftwareTechnology Services Pepgen Ltd. engages in research and experimental development on biotechnology. The company was founded on January 25, 2018 and is headquartered in Oxford, the United Kingdom. | Technology Services |
Albumedix Ltd.
Albumedix Ltd. BiotechnologyHealth Technology Part of Sartorius AG, Albumedix Ltd. is a British science-driven company and recognized leader of albumin-enabled solutions. The private company, based in Nottingham, UK, was founded in 1984 with a mission to empower excellence. Albumedix has supported its life-science partners in delivering safe doses of clinical and marketed therapeutics. The company's solutions include the world's only USP-NF compliant recombinant human albumin, client-centric development and compliance services, and drug-enhancing technologies. By challenging the status quo and striving for more, Albumedix enables the development and commercialization of advanced therapies and next-generation biopharmaceuticals. Albumedix is the world leader in recombinant human albumin and has developed a portfolio of products known as Recombumin®. Founded in 1973, the CEO of Albumedix is Jonas S. Moller. The company was acquired by Sartorius Stedim Biotech SA on September 30, 2022, for $500.47 million. | Health Technology |
- Borsa valori
- Insiders
- Giles Campion
- Esperienza